Breath Analysis by Ion Mobility Spectrometry

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT00632307
Recruitment Status : Recruiting
First Posted : March 10, 2008
Last Update Posted : March 6, 2018
Information provided by (Responsible Party):
Michael Westhoff MD, Lung Clinic Hemer

February 29, 2008
March 10, 2008
March 6, 2018
July 2006
June 2023   (Final data collection date for primary outcome measure)
Identification of diseases specific VOCs [ Time Frame: years ]
Not Provided
Complete list of historical versions of study NCT00632307 on Archive Site
Change of disease specific VOCs under therapy [ Time Frame: years ]
Not Provided
Not Provided
Not Provided
Breath Analysis by Ion Mobility Spectrometry
Detection of Clusters of Volatile Organic Compounds (VOC)in Patients With Different Lung Disorders by Ion Mobility Spectrometry. Different Clusters of VOC in the Diagnosis of Different Lung Disorders Using Ion Mobility Spectrometry

Recognition of disease specific clusters of volatile organic compounds in patients with different lung diseases, using breath analysis with ion mobility spectrometry. Lung diseases of interest are:

  • COPD
  • tumors
  • airway infection
  • interstitial lung disease
  • sleep apnea Hypothesis: Breath analysis with ion mobility spectrometry can differentiate pulmonary disorders.
Recruitment of patients with different lung diseases goes on. First sub-group analysis of patients with COPD,lung cancer and sarcoidosis is done in order to create a training set of VOC-clusters for further validation in a bigger population of patients.
Observational Model: Other
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
breath, pleural fluid (only in patients with therapeutic pleurocentesis)
Non-Probability Sample
patients of the lung clinic hemer with pulmonary diseases.
Lung Diseases
Not Provided
  • 1
  • 2
    lung cancer
  • 3
    airway infection
  • 4
    interstitial lung disease
  • 5
    sleep apnea
  • 6
    pulmonary disorders with pleural infusions
  • 7
  • 8
    healthy persons

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
June 2023
June 2023   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Any patient
  • Ages 18-90 years old

Exclusion criteria:

- Patient who are not able to perform an exhalation manoever.

Sexes Eligible for Study: All
18 Years to 90 Years   (Adult, Senior)
Contact: Michael Westhoff, MD 004923729082203
Contact: Patric Litterst, MD 004923729082545
Not Provided
Not Provided
Michael Westhoff MD, Lung Clinic Hemer
Lung Clinic Hemer
Not Provided
Principal Investigator: Michael Westhoff, MD Lung Clinic Hemer, 58675 Hemer, Germany
Lung Clinic Hemer
March 2018